Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR 173.82
+0.32 (0.18%)
At close: Dec 5, 2025
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€570,643
Profits / Employee
€155,552
Market Cap
418.20B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 318,000 |
| Allianz SE | 156,626 |
| Deutsche Telekom AG | 198,194 |
| Siemens Energy AG | 103,000 |
| Rheinmetall AG | 28,539 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Johnson & Johnson News
- 17 hours ago - JNJ releases new data bolstering Inlexzo for bladder cancer - Seeking Alpha
- 18 hours ago - Johnson & Johnson's (JNJ) SunRISe-1 Study Shows Promising Results for Bladder Cancer Treatment - GuruFocus
- 18 hours ago - Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC - PRNewsWire
- 1 day ago - Guggenheim Raises Price Target for JNJ to $227, Maintains 'Buy' Rating | JNJ Stock News - GuruFocus
- 1 day ago - Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi - Nasdaq
- 1 day ago - Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note - Nasdaq
- 1 day ago - Johnson & Johnson at Citi Global Healthcare Conference Transcript - GuruFocus
- 1 day ago - Johnson & Johnson Named Top Dividend Stock With Insider Buying and 2.53% Yield (JNJ) - Nasdaq